Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific Antibody (Research Grade) from ProteoGenix; catalogue PX-TA1067; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Blinatumomab biosimilar is a recombinant bispecific antibody targeting CD19 and CD3E, developed for research applications in immuno-oncology and T-cell engager studies. This research-grade antibody reproduces the mechanism of action of Blinatumomab by redirecting cytotoxic T cells toward CD19-expressing B cells.
Produced under strict quality control, this recombinant antibody is suitable for a wide range of immunotherapy, leukemia, and lymphoma research studies.
ProteoGenix provides high-quality research antibodies at competitive pricing, enabling laboratories to access reliable reagents for advanced immunology and oncology research.
This Blinatumomab biosimilar antibody is available for research use with flexible purchasing options depending on quantity and project requirements.
This antibody can be used in:
ProteoGenix catalogue number PX-TA1067. For research use only.
Target: Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific; Clonality: Monoclonal Antibody; Expression system: Mammalian; Purity: >85%; Molecular weight: 54.1kDa; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Blinatumomab Biosimilar – Anti-CD19/CD3E Bispecific |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
